Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis

MT Newswires Live06-30

Akebia Therapeutics (AKBA) and US Renal Care said Tuesday that the VOICE trial, evaluating Vafseo for the treatment of anemia in hemodialysis patients with end-stage kidney disease, was stopped after an interim analysis showed a decline in hospitalizations.

The parties said that the trial was halted after a recommendation from the Independent Data Monitoring Committee and Trial Steering Committee based on the prespecified criteria.

The decision was supported by findings of significantly improved safety outcomes in patients who were on a three-times-weekly Vafseo dosing regimen, compared with those who were given a standard-of-care erythropoiesis-stimulating agent, they said.

Akebia and US Renal Care are expected to present data from the analysis at an upcoming scientific meeting, they added.

Akebia shares were up 6.3% in Tuesday's premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647556087?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 20:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647556087","market":"us","top_or_hot":-1,"title":"Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis","media":"MT Newswires Live","content":"<html><body><p> Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AKBA) and US Renal Care said Tuesday that the VOICE trial, evaluating Vafseo for the treatment of anemia in hemodialysis patients with end-stage kidney disease, was stopped after an interim analysis showed a decline in hospitalizations.</p><p>The parties said that the trial was halted after a recommendation from the Independent Data Monitoring Committee and Trial Steering Committee based on the prespecified criteria.</p><p>The decision was supported by findings of significantly improved safety outcomes in patients who were on a three-times-weekly Vafseo dosing regimen, compared with those who were given a standard-of-care erythropoiesis-stimulating agent, they said.</p><p>Akebia and US Renal Care are expected to present data from the analysis at an upcoming scientific meeting, they added.</p><p>Akebia shares were up 6.3% in Tuesday's premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-30 20:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AKBA) and US Renal Care said Tuesday that the VOICE trial, evaluating Vafseo for the treatment of anemia in hemodialysis patients with end-stage kidney disease, was stopped after an interim analysis showed a decline in hospitalizations.</p><p>The parties said that the trial was halted after a recommendation from the Independent Data Monitoring Committee and Trial Steering Committee based on the prespecified criteria.</p><p>The decision was supported by findings of significantly improved safety outcomes in patients who were on a three-times-weekly Vafseo dosing regimen, compared with those who were given a standard-of-care erythropoiesis-stimulating agent, they said.</p><p>Akebia and US Renal Care are expected to present data from the analysis at an upcoming scientific meeting, they added.</p><p>Akebia shares were up 6.3% in Tuesday's premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647556087","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647556087","pubTimestamp":1782824253,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Akebia Therapeutics (AKBA) and US Renal Care said Tuesday that the VOICE trial, evaluating Vafseo for the treatment of anemia in hemodialysis patients with end-stage kidney disease, was stopped after ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AKBA":"Akebia Therapeutics, Inc."},"translate_title":"Akebia Therapeutics与US Renal Care在中期分析呈阳性后停止肾脏疾病试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1.5},"content_text":"Akebia Therapeutics (AKBA) and US Renal Care said Tuesday that the VOICE trial, evaluating Vafseo for the treatment of anemia in hemodialysis patients with end-stage kidney disease, was stopped after an interim analysis showed a decline in hospitalizations.The parties said that the trial was halted after a recommendation from the Independent Data Monitoring Committee and Trial Steering Committee based on the prespecified criteria.The decision was supported by findings of significantly improved safety outcomes in patients who were on a three-times-weekly Vafseo dosing regimen, compared with those who were given a standard-of-care erythropoiesis-stimulating agent, they said.Akebia and US Renal Care are expected to present data from the analysis at an upcoming scientific meeting, they added.Akebia shares were up 6.3% in Tuesday's premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647556087","isCrawlerRequest":true}